ライフサイエンスコーパス: renal

1 old increase in bioavailability, and reduced renal accumulation.

2 te fluid homeostasis and arterial BP through renal actions involving increased GFR and vascular and t

3 Renal adenosine levels were lower before and after ische

4 The rates of renal adverse events were similar in the liraglutide gro

5 ranged from 5 weeks for skin to 15 weeks for renal AEs.

6 ferentiation of prerenal and intrinsic acute renal allograft failure.

7 t with a Syk inhibitor significantly reduced renal allograft injury in a model of severe antibody-med

8 All causes of renal allograft injury, when severe and/or sustained, ca

9 rejection (AR) is a risk factor for inferior renal allograft outcome.

10 f 19 months, there was 100% (death-censored) renal allograft survival with estimated glomerular filtr

11 D) transplants, analyzing 3-year patient and renal allograft survival.

12 four had CKD stage 1-4, five had received a renal allograft, and three were dialysis-dependent at st

13 ases IRI and subsequent tissue injury in DCD renal allografts in a large animal transplant model.

14 detected the mutant peptide in the proband's renal amyloid deposits.

15 macroalbuminuria, long-term risk factors for renal and cardiovascular disease.

16 cating differential regulation of Cyp27b1 in renal and non-renal cells and has implications for vitam

17 medical conditions (hemodynamic, biological, renal, and liver insults) than donors without extracorpo

18 is regulated at the central nervous system, renal, and vascular levels, but the cell-specific role o

19 than 170 mm Hg at second screening underwent renal angiography and were randomly assigned to renal de

20 promoted DC-dependent cross-presentation of renal antigens to CD8 T cells in the draining lymph node

21 perivascular fat compartment located around renal arteries.

22 nterline diameter and volume from the lowest renal artery to the iliac bifurcation were the most sens

23 mbrane, and can always be traced back to the renal artery.

24 e sarcopenia index using routinely available renal biomarkers and evaluate its association with muscl

25 ic GN, with the aim of identifying potential renal biomarkers; several characteristic mid-IR spectral

26 on of SGLT2 mRNA and protein is increased in renal biopsies from human subjects with diabetic nephrop

27 tions were reviewed in 431 CT-guided medical renal biopsies performed between July 2007 and September

28 increased IL-36alpha expression detected in renal biopsy specimens and urine samples from patients w

29 necessary for the pathogenesis of clear cell renal cancer (ccRCC); however, the molecular mechanisms

30 t MCPIP1 protein levels are decreased during renal cancer progression.

31 Activating the renal cannabinoid-1 receptor (CB1R) induces nephropathy,

32 l cortical surface, at a depth closer to the renal capsule than the renal pelvic fat.

33 itize TRAIL-mediated apoptosis in a panel of renal carcinoma cells.

34 n of chromatin-modifying genes in clear cell renal cell carcinoma (ccRCC) has been uncovered through

35 protein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC).

36 BDs and is frequently mutated in clear cell renal cell carcinoma (ccRCC).

37 us a tyrosine kinase inhibitor in metastatic renal cell carcinoma (mRCC).

38 For the past decade, advanced renal cell carcinoma (RCC) has been at the forefront of

39 Renal cell carcinoma (RCC) is a cancer with poor prognos

40 ies (GWAS) have identified six risk loci for renal cell carcinoma (RCC).

41 mg/kg in patients with melanoma (n = 16) and renal cell carcinoma (RCC; n = 15).

42 r prediction of local tumor recurrence after renal cell carcinoma ablation.

43 Renal cell carcinoma has long been understood to have a

44 resent the case of endovascular treatment of renal cell carcinoma in patient with solitary kidney.

45 71.9 years +/- 10.9) with 217 biopsy-proven renal cell carcinoma tumors treated with thermal ablatio

46 ment-naive progressive metastatic clear cell renal cell carcinoma were enrolled between September 201

47 on correlates with poor clinical outcomes in renal cell carcinoma.

48 expressed in kidney, and is downregulated in renal cell carcinoma; also, its low expression correlate

49 ntial regulation of Cyp27b1 in renal and non-renal cells and has implications for vitamin D biology i

50 atrix protein increase by activating AMPK in renal cells, we examined whether H2S inhibits high gluco

51 Histopathological diagnosis was renal clear cell carinoma.

52 t that the pharmacokinetics and clearance of renal clearable gold nanoparticles (GS-AuNPs) are strong

53 labeled C2Am derivative showed predominantly renal clearance and high specificity and sensitivity for

54 We observed that the renal concentration mechanism couples natriuresis with c

55 -inducible factor-1alpha upregulation in the renal cortex.

56 roach if the needle path was parallel to the renal cortical surface, at a depth closer to the renal c

57 Estimated renal creatinine clearance correlated with the extent of

58 ding Crb3 and Wwtr1/Taz, have been linked to renal cyst formation in mice before.

59 transplant recipients from the United States Renal Data System (USRDS) database from the years 2004 t

60 We linked the United States Renal Data System data set to Medicare claims to estimat

61 We examined United States Renal Data System records of Medicare-insured kidney tra

62 ent hemodialysis >/=67 years old from the US Renal Data System with linked Medicare claims to identif

63 The capacity of renal DCs to present antigen was examined by assessment

64 the genetic cause of cardiac, vertebral, and renal defects, among others, in unrelated patients.

65 ction in snap29, aifm3, and crkl resulted in renal defects; the loss of crkl alone was sufficient to

66 al angiography and were randomly assigned to renal denervation or sham control.

67 10 unit change in renal elasticity for rapid renal deterioration was 0.928 (95% CI, 0.864-0.997; P =

68 on between serum 1,5-AG levels and end-stage renal disease (ESRD) from baseline (1990-1992) through 2

69 atitis C virus (HCV) infection and end-stage renal disease (ESRD) remains controversial without consi

70 ts with CKD, especially those with end-stage renal disease (ESRD), are controversial.

71 was associated with development of end-stage renal disease (ESRD).

72 nsion (AASK) and 761 Modification of Diet in Renal Disease (MDRD) Trial participants previously rando

73 calculated using the Modification of Diet in Renal Disease formula.

74 longer survival, the prevalence of end-stage renal disease in HIV is increasing.

75 , and assess relevant risk factors including renal disease, antiphospholipid antibody, and anti-Ro/SS

76 hich has been observed in the progression of renal disease, contributes to GN progression.

77 agonist anti-Ox40 mAbs potently exacerbated renal disease, which was accompanied by activation of ki

78 uced risk of future progression to end-stage renal disease.

79 T2 inhibition in the progression of diabetic renal disease.

80 ients, including patients with non-end-stage renal disease.

81 ependent contributions of these disorders to renal disease.

82 erate personalized in vivo models of genetic renal diseases bearing patient-specific mutations.

83 involved in the pathogenesis of cardiac and renal diseases, and in the progression of tumour growth

84 t alleles are at elevated risk of developing renal diseases.

85 s new drug targets to treat APOL1-associated renal diseases.

86 grade 3 disorders included hepatobiliary and renal disorders (three [13%] at 200 mg twice a day), ast

87 preexisting coronary artery disease reduced renal dysfunction and cardiac injury, potentially result

88 Liver transplant candidates with advanced renal dysfunction and HCC may be considered for SLK.

89 ation using serelaxin as a new treatment for renal dysfunction in cirrhosis, although further validat

90 eatment with serelaxin prevented cardiac and renal dysfunction in DOCA-salt rats.

91 in patients with more advanced cirrhosis and renal dysfunction is required.

92 Encephalopathy, hepatic, and renal dysfunction manifested later than cardiovascular a

93 Age, B-type natriuretic peptide level, renal dysfunction, 24-h AHI, CAI, and time with oxygen s

94 induced lipid accumulation in the kidney and renal dysfunction, injury, inflammation, and fibrosis.

95 association between hemoglobin and brain or renal dysfunction, or ICU mortality.

96 ients had lower rates of DGF (5% vs 20%) and renal dysfunction-related readmissions (10% vs 27.5%) (P

97 or prognosis, especially in individuals with renal dysfunction.

98 l, the odds ratio (OR) per 10 unit change in renal elasticity for rapid renal deterioration was 0.928

99 ates of complete remission and the composite renal end point did not differ significantly between gro

100 Biopsies revealed elevated renal ENDATs in most participants, but ENDATs were not r

101 PD and/or CS-exposed mice have pulmonary and renal endothelial cell injury linked to increased endoth

102 is is the most extensive analysis of primary renal epithelial cells from JBTS patients to date.

103 As proof of concept, cultured renal epithelial cells were exposed to urinary exosomes

104 tissue specificity for islet beta cells and renal epithelial cells were reliably characterized in re

105 ssion induces profound autophagy in cultured renal epithelial cells.

106 se inter-relationship of capillaries and the renal epithelium is key to renal physiology, but how ren

107 re-treatment with ABT-627 failed to decrease renal ER stress and apoptosis in ETB def rats.

108 t for the development of tunicamycin-induced renal ER stress and apoptosis.

109 major adverse cardiac, cerebrovascular, and renal events at 1 month.

110 above 15 mg kg(-1) : high dose expedited the renal excretion and shortened the blood retention.

111 Moreover, the renal excretion kinetic and intrahepatic albumin binding

112 We hypothesized that renal expression of podocyte-specific proteins would be

113 d to treatment), pneumonia (27 [11%]), acute renal failure (25 [10%]; five related to treatment), pyr

114 e events (RR: 1.02; 95% CI: 0.94 to 1.09) or renal failure (RR: 1.81; 95% CI: 0.86 to 3.80) between t

115 and urinary sepsis in one patient, and acute renal failure and respiratory failure in one patient) we

116 erbilirubinemia and/or Encephalopathy and/or Renal Failure trial by applying the recently introduced

117 (range, 1-41) years in 77 patients, chronic renal failure was detected in 19 patients (25%): one req

118 In the latter patient, acute renal failure was not suspected to be related to everoli

119 cement therapy (CRRT) benefits patients with renal failure who are too hemodynamically unstable for i

120 phthisis, typically progressing to end-stage renal failure within the first two decades of life, thus

121 of upper limb ischemia - diabetes, end-stage renal failure, hyperparathyroidism, or even symptoms of

122 pment of HUS, complications (ie, oligoanuric renal failure, involvement of the central nervous system

123 Conclusion In the absence of known renal failure, neonates receiving standard inpatient car

124 ritis or interstitial nephritis, as cause of renal failure, represented the only predictive factor fo

125 cantly later with comorbid heart failure and renal failure, with absence of fever or hypotension, and

126 loop that regulates FGF23 expression during renal failure.

127 of diabetes mellitus and possibly of chronic renal failure.

128 and in the kidney, it predicts the onset of renal failure.

129 a common cause of childhood hypertension and renal failure.

130 limited, but suggested an increased risk of renal failure.

131 A hallmark of CKD progression is renal fibrosis characterized by excessive accumulation o

132 CKD and replicated, five also associate with renal fibrosis in biopsies from CKD patients and show co

133 of miR-194-dependent MMPs and PARP-1 causes renal fibrosis in diabetes kidney, and whether H2S ameli

134 (TNF-alpha) play key roles in progression of renal fibrosis, dual blockade of TGF-beta1 and TNF-alpha

135 deal of a noninvasive image-based measure of renal fibrosis.

136 al uptake in the fibrotic kidney and reduced renal fibrosis.

137 orsened eGFR (>/=10% lower), or no change in renal function (neither).

138 nvestigation as a more meaningful measure of renal function after critical illness.

139 Renal function and histologic morphology were evaluated.

140 5 mg twice daily) in patients with preserved renal function and might be a reasonable alternative to

141 e patients is often mild and does not impact renal function at day 30, while infection/ sepsis is the

142 Renal function did not worsen on LDV/SOF regimens with T

143 e associated with NS play conserved roles in renal function from flies to humans.

144 Even in healthy individuals, renal function gradually declines during aging.

145 rom patients with renal TILs correlated with renal function impairment.

146 7 that have not previously been analysed for renal function in an animal model.

147 mplete reversal of hypertension and improved renal function in CKD-RDN sheep (p < 0.0001 for 2 and 5

148 ized that the hepatokine fetuin-A may impair renal function in non alcoholic fatty liver disease (NAF

149 0L and sCD40R are associated with changes in renal function in patients with CKD.

150 llent patient and graft survival, and stable renal function over 4 years.

151 alpha, interleukins, hemogram, and liver and renal function tests were performed at days 0 and 5.

152 The magnitude of decline in renal function that should be tolerated during intensive

153 on (APACHE) II score, severity of sepsis and renal function were enrolled.

154 the effect of RDN on mean arterial pressure, renal function, and the reflex response to hemorrhage in

155 es the effects of rifaximin on hemodynamics, renal function, and vasoactive hormones.

156 Among ICU patients with stable renal function, the benefit of using sodium bicarbonate

157 for the 5-mg dose in patients with preserved renal function.

158 onin (hs-cTn) concentrations irrespective of renal function.

159 w risk, and better correlated with follow-up renal function.

160 emia, though none had rapid deterioration of renal function.

161 several microRNAs correlated with indexes of renal function.

162 ned whether this association was modified by renal function.

163 h) for 7-14 days; regimens were adjusted for renal function.

164 iated with serum levels of IS independent of renal function.

165 rome (SRNS), a heterogeneous disorder of the renal glomerular filtration barrier, results in impairme

166 Outer retinal and renal glomerular functions rely on specialized vasculatu

167 ied a cohort of 60 individuals with familial renal glucosuria.

168 investigated the possible salutary effect of renal GPCR-Gbetagamma inhibition in CKD developed in a c

169 KD secondary to CHF associated with elevated renal GPCR-Gbetagamma signaling and ET system expression

170 e, be a useful marker for cardiovascular and renal health.

171 Rat brain and renal, hepatic, and splenic tissues were harvested 7 day

172 Renal histologic expression of the podocyte-specific pro

173 ed, concomitant with ameliorated cardiac and renal hypertrophy.

174 otective effect of microbiota depletion upon renal I/R injury.

175 infection was independently associated with renal impairment (adjusted odds ratio [aOR] = 2.1; 95% c

176 diac troponin identified fewer patients with renal impairment as low risk and more as high risk, but

177 isk factors for osteonecrosis of the jaw and renal impairment should be assessed, and any pending den

178 gulation therapy, and substantial hepatic or renal impairment.

179 Among the 1,473 patients with a renal indication for dose reduction, 43.0% were potentia

180 show that inhibition of BET proteins reduces renal inflammation by several mechanisms: chromatin remo

181 t of DOCA-salt rats with serelaxin decreased renal inflammation, including the expression of TGF-beta

182 Interestingly, both the renal injury and dysfunction in wild-type mice undergoin

183 Warfarin-associated calciphylaxis without renal injury has been described, but whether it is a sub

184 Furthermore, renal injury in preeclampsia associated with an elevated

185 iron accumulation occurs and contributes to renal injury in SLE.

186 H2 S treatment mitigates cold IRI-associated renal injury via mitochondrial actions and could represe

187 Acute tubular and glomerular renal injury was accompanied by nonheme iron deposition

188 otected against ischemia-reperfusion-induced renal injury.

189 particularly in these patients who may have renal insufficiency.

190 Renal intercalated cells (ICs) express the proton pumpin

191 ins nephron progenitor cells by repressing a renal interstitial cell program.

192 age, and cutaneous, abdominal, articular, or renal involvement.

193 ody to inhibit alphavbeta5 in a rat model of renal IRI.

194 We tested the hypothesis that renal iron accumulation occurs and contributes to renal

195 indings suggest that pathological changes in renal iron homeostasis occurs in lupus nephritis, contri

196 ive effect of amniotic fluid stem cells in a renal ischemia-reperfusion injury model.

197 human amniotic fluid stem cells in rats with renal ischemia-reperfusion injury, mainly by mitogenic,

198 3 hours) treatment with necrostatin-1 during renal ischemia-reperfusion injury.

199 Despite treatment improvements, associated renal lesions - congenital dysplasia, acquired scarring

200 roves the characterization of small (1-4 cm) renal lesions compared with conventional attenuation mea

201 ntiation between benign and malignant cystic renal lesions.

202 oneal injection of GC7 substantially reduced renal levels of hypusinated eIF5A and protected against

203 SGLT2 inhibition prevented renal lipid accumulation via inhibition of carbohydrate-

204 study showed that SGLT2 inhibition modulates renal lipid metabolism and inflammation and prevents the

205 The renal manifestation of JBTS is a juvenile-onset cystic k

206 the lack of efficacious treatments targeting renal manifestations of the disease.

207 ced hypertension; and early mortality in the renal mass reduction model.

208 distinguishing between benign and malignant renal masses.

209 AKI is a frequent condition that involves renal microcirculation impairment, infiltration of infla

210 ved in the maintenance and protection of the renal microvascular endothelium.

211 ), which then phosphorylate and activate the renal Na-Cl cotransporter (NCC).

212 ll increase in the affected kidneys, whereas renal neutrophil numbers were not affected.

213 Although short-term renal outcome was good in most women, long-term renal ou

214 al outcome was good in most women, long-term renal outcome was poor; among the 14 women, four had CKD

215 between these biomarkers of inflammation and renal outcomes in DKD.

216 ver, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unkn

217 sers of H2 blockers (H2B; n = 9578); data on renal outcomes were collected for a median 2.7 years.

218 ad no effect on functional expression of the renal outer medullary potassium channel.

219 erstitial fibrosis are associated with lower renal parenchymal elasticity.

220 tin-binding deficient ABIN1[D485N] mice, and renal pathophysiology and glomerular inflammatory phenot

221 a depth closer to the renal capsule than the renal pelvic fat.

222 Hydrodynamic renal pelvis injection enables transposon mediated-kidne

223 cidence for all urothelial cancers combined (renal pelvis, ureter, and bladder cancers: adjusted IRR

224 lved in vitamin D metabolism and calcium and renal phosphate transport associated with differences in

225 pillaries and the renal epithelium is key to renal physiology, but how renal tubules regulate capilla

226 TRPP2-PKD1 complex has a crucial function in renal physiology, with mutations in either protein causi

227 PUA, GFR (inulin), effective renal plasma flow (para-aminohippurate), BP, and hemodyn

228 ling in murine intermediate mesoderm-derived renal progenitors results in hydronephrosis and failure

229 nd S1 segments of proximal tubules, and full renal protection required both macrophages and renal tub

230 via the activation of NF-kappaB in cultured renal proximal tubular cells.

231 e show that specific deletion of CB1R in the renal proximal tubule cells did not protect the mice fro

232 been associated with mortality and impaired renal recovery.

233 even fluid balance, on 1-year mortality and renal recovery.

234 Data from the Norwegian Renal Registry with all renal transplanted men alive bet

235 Continuous renal replacement therapy (CRRT) benefits patients with

236 HUS (OR, 2.38 [95% CI, 1.30-4.35]; I2 = 2%), renal replacement therapy (OR, 1.90 [95% CI, 1.25-2.90];

237 , which was attenuated in those who received renal replacement therapy (positive fluid balance x rena

238 oneal dialysis (PD) is a life-saving form of renal replacement therapy for those with end-stage kidne

239 eplacement therapy (positive fluid balance x renal replacement therapy interaction (adjusted hazard r

240 Continuous renal replacement therapy using blood flow rate set at 2

241 Continuous renal replacement therapy without anticoagulation was mo

242 us system, or death), and interventions (ie, renal replacement therapy).

243 ative extracorporeal membrane oxygenation or renal replacement therapy, severe preimplant tricuspid r

244 Critically ill adults requiring continuous renal replacement therapy.

245 component composite of death through day 30, renal-replacement therapy through day 30, perioperative

246 increased use of mechanical ventilation and renal-replacement therapy.

247 ar filtration rate (P < 0.001), and improved renal resistive index (P < 0.001) and kidney microcircul

248 ysfunction of at least 1 organ system of the renal, respiratory, cardiovascular, coagulation, and neu

249 ites, which could be attributed to the APOL1 renal risk variants.

250 proxil fumarate, thereby minimising bone and renal risks.

251 These findings support the short-term renal safety of TDF/FTC PrEP in HIV-seronegative young m

252 Bartter syndrome phenotype, characterized by renal salt loss, marked hypokalemia, and metabolic alkal

253 enabled us to obtain a completely acellular renal scaffold while maintaining the extracellular matri

254 gical diagnosis was monoclonal gammopathy of renal significance in 30 (60%), multiple myeloma in 17 (

255 Renal sinus fat (RSF) is a perivascular fat compartment

256 However, whether T cells contribute to renal sodium retention and salt-sensitive hypertension i

257 jection of recombinant cKL downregulated the renal sodium-phosphate cotransporter Npt2a in alphaKL-nu

258 Our data show that Troy marks a renal stem/progenitor cell population in the developing

259 persistent hematuria had significantly worse renal survival than those in the other three groups.

260 oteinuria >0.75 g/d had significantly poorer renal survival than those with time-averaged proteinuria

261 ecimens and urine samples from patients with renal TILs correlated with renal function impairment.

262 ppear to be at increased risk for developing renal toxicity due to administration of intravenous iodi

263 to be safe and effective for patients after renal transplant and is a promising treatment regimen fo

264 66.9 [12.5] years), and 2980 patients in the renal transplant group (27.3% women; 72.7% men; mean [SD

265 y and safety of sofosbuvir and ledipasvir in renal transplant patients with chronic HCV infection.

266 ABO-incompatible renal transplant performed with antibody removal and con

267 C virus (HCV) infection is prevalent in the renal transplant population but direct acting antiviral

268 approximately 800 patients in the cohort of renal transplant recipients at our institution, 15 subje

269 arge national data registry used a cohort of renal transplant recipients from the United States Renal

270 Among renal transplant recipients with STEMI, the use of reper

271 one required hemodialysis and four underwent renal transplant.

272 Renal transplantation (from the same BMT donor) was perf

273 significant mutation in INF2 In this family, renal transplantation was associated with post-transplan

274 During the first year after renal transplantation, 14 patients developed severe infe

275 In the clinical settings of islet and renal transplantation, donor exosomes with respective ti

276 ple aortic aneurysms, respectively underwent renal transplantation.

277 main higher with chronic dialysis than after renal transplantation.

278 a from the Norwegian Renal Registry with all renal transplanted men alive between January 1, 1995 and

279 udy, we assessed the outcome of all (n = 95) renal transplanted patients with pretransplant cancer di

280 The other control group comprised the entire renal transplanted population in Uppsala.

281 The 7 preceding living donor renal transplants performed using the standard arterial

282 es after deceased donor but not living donor renal transplants, thus donor death and organ preservati

283 ch correlated with significant impairment of renal Treg infiltration.

284 arly-onset sensorineural deafness and distal renal tubular acidosis.

285 nal protection required both macrophages and renal tubular cells.

286 (aOR = 5.8; 95% CI = 3.7-9.0), and proximal renal tubular dysfunction (aOR = 7.0; 95% CI = 4.9-10.2]

287 he increased expression of IL-36alpha in the renal tubular epithelial cells of a mouse model of unila

288 ecognized a high molecular weight protein in renal tubular protein extracts that we identified as LDL

289 icate that miR-146a is a key mediator of the renal tubular response to IRI that limits the consequenc

290 e kidney glomerulus and is reabsorbed in the renal tubule by the action of the apical sodium-dependen

291 Earlier work identified renal tubule cell synthesis of C3, rather than hepatic s

292 with conditional inactivation of Xpr1 in the renal tubule exhibited generalized proximal tubular dysf

293 Chloride transport by the renal tubule is critical for blood pressure (BP), acid-b

294 In the Malpighian (renal) tubule of Drosophila melanogaster, TA activates a

295 ithelium is key to renal physiology, but how renal tubules regulate capillary development remains unc

296 roximal tubular cells or in freshly isolated renal tubules revealed that this Xpr1 deficiency signifi

297 transgene, a predominant isoform of PHDs in renal tubules, to reduce HIF-1alpha level significantly

298 Importantly, simultaneous patients had more renal vascular thromboses (4.4% vs 1.3% tx alone, 0% pre

299 ggest the therapeutic potential of selective renal vasodilation using serelaxin as a new treatment fo

300 anism couples natriuresis with correspondent renal water reabsorption, limits natriuretic osmotic diu